Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 3 Trial of Setmelanotide (RM-493), a Melanocortin-4 Receptor (MC4R) Agonist, in Bardet-Biedl Syndrome (BBS) and Alström Syndrome (AS) Patients With Moderate to Severe Obesity

NCT03746522 is registered in ClinicalTrials.gov with Rhythm Pharmaceuticals, Inc. as lead sponsor.

NCT NCT03746522
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03746522 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 3 Trial of Setmelanotide (RM-493), a Melanocortin-4 Receptor (MC4R) Agonist, in Bardet-Biedl Syndrome (BBS) and Alström Syndrome (AS) Patients With Moderate to Severe Obesity
Lead sponsor
Rhythm Pharmaceuticals, Inc.
Phase
Phase 3
Overall status
Completed
Start date
November 23, 2018
Completion date
March 8, 2021
Enrollment
52 (actual)
Sites
12

Conditions

As the registry lists them; a condition with its own page is linked.

alström syndrome (as), bardet biedl syndrome (bbs)